SENATE BILL No. 1055

 

 

June 7, 2018, Introduced by Senators SCHUITMAKER, KOWALL, COLBECK, EMMONS, HUNE and SHIRKEY and referred to the Committee on Health Policy.

 

 

 

     A bill to amend 1978 PA 368, entitled

 

"Public health code,"

 

(MCL 333.1101 to 333.25211) by adding section 9206a.

 

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

 

     Sec. 9206a. (1) The department shall create and maintain a

 

list of each immunizing agent derived from aborted fetal tissue. If

 

an immunizing agent that is not an immunizing agent derived from

 

aborted fetal tissue is available as an alternative to an

 

immunizing agent derived from aborted fetal tissue, the department

 

shall include the alternative on the list. The department shall

 

update the list annually and make the list available to the public

 

on the department's website.

 

     (2) Before administering an immunizing agent derived from

 

aborted fetal tissue to an individual, a health care provider shall

 

notify the individual or, if the individual is a child, the parent,

 

guardian, or person in loco parentis of the child, that the

 

immunizing agent was derived from aborted fetal tissue. If an

 

immunizing agent that is not an immunizing agent derived from

 

aborted fetal tissue is available as an alternative to an

 

immunizing agent derived from aborted fetal tissue, the health care

 

provider shall offer the alternative to the individual or, if the

 

individual is a child, the parent, guardian, or person in loco

 

parentis of the child.A health care provider shall also notify the

 

individual or, if the individual is a child, the parent, guardian,

 

or person in loco parentis of the child, of the option to decline

 

the receipt of the immunizing agent.

 

     (3) As used in this section:

 

     (a) "Health care provider" means that term as defined in

 

section 9206.

 

     (b) "Immunizing agent derived from aborted fetal tissue" means

 

an immunizing agent that is manufactured using a human fetal or

 

embryonic cell line, protein, deoxyribonucleic acid, recombinant

 

deoxyribonucleic acid, monoclonal antibody, or any other component

 

derived from an elective abortion or using a cell line derived from

 

the tissue of a fetus that was electively aborted.

 

     Enacting section 1. This amendatory act takes effect 90 days

 

after the date it is enacted into law.